SINGAPORE (Dec 17): Clearbridge Health, which has seen its share price lose half its value this year, is spinning off its cancer diagnostics associate Biolidics for a Catalist listing. Biolidics, which has plans to expand in China, is placing out 27.5 million shares at 28 cents apiece, raising gross proceeds of $7.7 million. Trading is slated to start on Dec 19. Just as Clearbridge was the last IPO of 2017, Biolidics is the last IPO this year. Similar to Clearbridge’s case, there is no public tranche for Biolidics.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply